Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved
November 16, 2016 at 15:30 PM EST
The biotech sector responded favorably to Trump’s victory on hopes that there will be fewer drug pricing headwinds considering Trump was not as vocal as Hillary Clinton about rising drug prices and excessive price hikes.
